0000850261
us-gaap:StateAndLocalJurisdictionMember
us-gaap:ResearchMember
2012-12-31
0000850261
us-gaap:ForeignCountryMember
us-gaap:ResearchMember
2012-12-31
0000850261
srne:EquityIncentivePlanMember
srne:UnvestedRestrictedStockMember
2011-01-01
2011-01-31
0000850261
srne:MayMember
us-gaap:AdditionalPaidInCapitalMember
2012-01-01
2012-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
srne:DecemberMember
2011-01-01
2011-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
srne:DecemberMember
2010-01-01
2010-12-31
0000850261
us-gaap:CommonStockMember
srne:SeptemberMember
2009-01-01
2009-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
srne:SeptemberMember
2009-01-01
2009-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
srne:JuneMember
2009-01-01
2009-12-31
0000850261
us-gaap:CommonStockMember
2012-01-01
2012-12-31
0000850261
us-gaap:CommonStockMember
2011-01-01
2011-12-31
0000850261
2013-03-01
2013-03-28
0000850261
us-gaap:CommonStockMember
srne:MayMember
2012-01-01
2012-12-31
0000850261
srne:HongyeSdGroupLlcMember
2012-01-01
2012-12-31
0000850261
us-gaap:CommonStockMember
srne:DecemberMember
2011-01-01
2011-12-31
0000850261
us-gaap:CommonStockMember
srne:DecemberMember
2010-01-01
2010-12-31
0000850261
us-gaap:CommonStockMember
srne:JuneMember
2009-01-01
2009-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2012-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2012-12-31
0000850261
srne:StockholderNoteReceivableMember
2012-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2011-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2011-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2010-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2010-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2009-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2009-12-31
0000850261
srne:StockholderNoteReceivableMember
2009-12-31
0000850261
2009-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2008-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2008-12-31
0000850261
2008-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2007-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2007-12-31
0000850261
2007-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2006-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2006-12-31
0000850261
2006-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2006-01-25
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2006-01-25
0000850261
srne:StockholderNoteReceivableMember
2006-01-25
0000850261
2006-01-25
0000850261
us-gaap:AdditionalPaidInCapitalMember
2012-01-01
2012-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2010-01-01
2010-12-31
0000850261
us-gaap:CommonStockMember
2012-12-31
0000850261
us-gaap:CommonStockMember
2011-12-31
0000850261
us-gaap:CommonStockMember
2010-12-31
0000850261
us-gaap:CommonStockMember
2009-12-31
0000850261
us-gaap:CommonStockMember
2008-12-31
0000850261
us-gaap:CommonStockMember
2007-12-31
0000850261
us-gaap:CommonStockMember
2006-12-31
0000850261
us-gaap:CommonStockMember
2006-01-25
0000850261
srne:PrivatePlacementTransactionMember
2013-03-28
0000850261
srne:StockPurchaseAgreementMember
2011-12-31
0000850261
srne:PrivatePlacementTransactionMember
2010-12-31
0000850261
srne:PrivatePlacementTransactionMember
srne:QuikByteMember
2009-09-30
0000850261
srne:OpkoMember
srne:TwoThousandNineEquityIncentivePlanMember
us-gaap:PrivatePlacementMember
2009-06-30
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
2011-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2010-12-31
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
2010-12-31
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
2012-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2011-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2011-01-01
2011-12-31
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
2011-01-01
2011-12-31
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
2012-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2009-12-31
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
us-gaap:StockOptionMember
2009-09-30
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
2009-02-28
0000850261
us-gaap:RestrictedStockMember
srne:TwoThousandNineEquityIncentivePlanMember
2012-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
us-gaap:StockOptionMember
2012-01-01
2012-12-31
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
2009-03-01
2009-03-31
0000850261
us-gaap:StockOptionsMember
2012-01-01
2012-12-31
0000850261
srne:StaphInfectionsMember
2012-01-01
2012-12-31
0000850261
srne:CollaborationAgreementMember
2012-01-01
2012-12-31
0000850261
srne:CDiffGrantAwardMember
2012-01-01
2012-12-31
0000850261
us-gaap:StockOptionsMember
2011-01-01
2011-12-31
0000850261
srne:CollaborationAgreementMember
2011-01-01
2011-12-31
0000850261
srne:CDiffGrantAwardMember
2011-01-01
2011-12-31
0000850261
us-gaap:StockOptionsMember
2006-01-26
2012-12-31
0000850261
srne:UsTreasuryGrantsMember
2006-01-26
2012-12-31
0000850261
srne:StaphInfectionsMember
2006-01-26
2012-12-31
0000850261
srne:CollaborationAgreementMember
2006-01-26
2012-12-31
0000850261
srne:CDiffGrantAwardMember
2006-01-26
2012-12-31
0000850261
us-gaap:MinimumMember
2012-01-01
2012-12-31
0000850261
us-gaap:MaximumMember
2012-01-01
2012-12-31
0000850261
us-gaap:OfficeEquipmentMember
2012-12-31
0000850261
us-gaap:LeaseholdImprovementsMember
2012-12-31
0000850261
us-gaap:FurnitureAndFixturesMember
2012-12-31
0000850261
us-gaap:EquipmentMember
2012-12-31
0000850261
us-gaap:OfficeEquipmentMember
2011-12-31
0000850261
us-gaap:LeaseholdImprovementsMember
2011-12-31
0000850261
us-gaap:FurnitureAndFixturesMember
2011-12-31
0000850261
us-gaap:EquipmentMember
2011-12-31
0000850261
srne:PrivatePlacementTransactionMember
2013-03-01
2013-03-28
0000850261
srne:StockPurchaseAgreementMember
2011-12-01
2011-12-31
0000850261
srne:PrivatePlacementTransactionMember
2010-12-01
2010-12-31
0000850261
srne:PrivatePlacementTransactionMember
srne:QuikByteMember
2009-09-01
2009-09-30
0000850261
srne:EquityIncentivePlanMember
2009-03-01
2009-03-31
0000850261
srne:UnrestrictedStockMember
srne:TwoThousandNineEquityIncentivePlanMember
us-gaap:CommonStockMember
2009-03-01
2009-03-31
0000850261
us-gaap:RestrictedStockMember
srne:TwoThousandNineEquityIncentivePlanMember
2009-03-01
2009-03-31
0000850261
srne:TwoThousandSixEquityIncentivePlanMember
2006-02-01
2006-02-28
0000850261
us-gaap:StateAndLocalJurisdictionMember
2012-12-31
0000850261
us-gaap:ForeignCountryMember
2012-12-31
0000850261
us-gaap:MinimumMember
2012-12-31
0000850261
us-gaap:MaximumMember
2012-12-31
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
us-gaap:CommonStockMember
srne:UnrestrictedStockMember
2009-03-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2012-01-01
2012-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2011-01-01
2011-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2010-01-01
2010-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2009-01-01
2009-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2008-01-01
2008-12-31
0000850261
2008-01-01
2008-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2007-01-01
2007-12-31
0000850261
2007-01-01
2007-12-31
0000850261
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2006-01-26
2006-12-31
0000850261
srne:CDiffGrantAwardMember
2012-12-31
0000850261
srne:QuikByteMember
2009-09-21
0000850261
2009-09-17
0000850261
2009-09-18
0000850261
srne:TsriMember
2012-12-31
0000850261
srne:StockPlanMember
2012-12-31
0000850261
srne:EquityIncentivePlanMember
2012-12-31
0000850261
2010-12-31
0000850261
us-gaap:WarrantMember
2012-01-01
2012-12-31
0000850261
us-gaap:StockOptionsMember
2012-01-01
2012-12-31
0000850261
srne:UnvestedRestrictedCommonStockSubjectToRepurchaseMember
2012-01-01
2012-12-31
0000850261
us-gaap:WarrantMember
2011-01-01
2011-12-31
0000850261
us-gaap:StockOptionsMember
2011-01-01
2011-12-31
0000850261
srne:UnvestedRestrictedCommonStockSubjectToRepurchaseMember
2011-01-01
2011-12-31
0000850261
2010-07-01
2010-07-31
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
srne:UnvestedRestrictedStockMember
2011-01-01
2011-01-31
0000850261
srne:TwoThousandTenEquityIncentivePlanMember
2010-12-01
2010-12-31
0000850261
srne:QuikByteMember
2009-09-01
2009-09-30
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
srne:OpkoMember
us-gaap:PrivatePlacementMember
2006-06-01
2009-06-30
0000850261
2006-01-26
2012-12-31
0000850261
srne:TwoThousandNineEquityIncentivePlanMember
2012-01-01
2012-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2012-12-31
0000850261
us-gaap:RetainedInterestMember
2012-12-31
0000850261
srne:QuikByteMember
2012-12-31
0000850261
us-gaap:PrivatePlacementMember
2009-09-18
0000850261
srne:UsTreasuryGrantsMember
2010-01-01
2010-12-31
0000850261
srne:InitailServiceAgreementMember
srne:IgDraSolIncMember
2013-03-07
0000850261
srne:DevelopmentServicesAgreementMember
srne:IgDraSolIncMember
2013-03-07
0000850261
srne:AssetPurchaseAgreementMember
srne:IgDraSolIncMember
2013-03-07
0000850261
srne:MarchMember
2009-01-01
2009-12-31
0000850261
srne:CDiffGrantAwardMember
2011-06-01
2011-06-30
0000850261
us-gaap:StockOptionsMember
2010-05-01
2010-05-31
0000850261
2013-02-01
2013-02-28
0000850261
us-gaap:GeneralAndAdministrativeExpenseMember
2012-01-01
2012-12-31
0000850261
us-gaap:GeneralAndAdministrativeExpenseMember
2011-01-01
2011-12-31
0000850261
us-gaap:GeneralAndAdministrativeExpenseMember
2006-01-26
2012-12-31
0000850261
srne:AssignmentAgreementMember
2012-01-01
2012-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2006-01-26
2006-12-31
0000850261
2006-01-26
2006-12-31
0000850261
us-gaap:CommonStockMember
2006-01-26
2006-12-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2009-01-01
2009-12-31
0000850261
srne:StockholderNoteReceivableMember
2009-01-01
2009-12-31
0000850261
2009-01-01
2009-12-31
0000850261
us-gaap:CommonStockMember
2009-01-01
2009-12-31
0000850261
srne:MayMember
2012-01-01
2012-12-31
0000850261
srne:DecemberMember
2011-01-01
2011-12-31
0000850261
srne:DecemberMember
2010-01-01
2010-12-31
0000850261
srne:SeptemberMember
2009-01-01
2009-12-31
0000850261
srne:JuneMember
2009-01-01
2009-12-31
0000850261
srne:StaphInfectionsMember
2012-06-01
2012-06-30
0000850261
2013-02-28
0000850261
2011-12-31
0000850261
srne:StockholderNoteReceivableMember
2010-01-01
2010-12-31
0000850261
2010-01-01
2010-12-31
0000850261
2012-12-31
0000850261
srne:IgDraSolIncMember
2013-03-07
0000850261
srne:IgDraSolIncMember
2013-03-01
2013-03-28
0000850261
srne:AssignmentAgreementMember
2013-01-31
0000850261
us-gaap:AdditionalPaidInCapitalMember
2011-01-01
2011-12-31
0000850261
2011-01-01
2011-12-31
0000850261
srne:AssignmentAgreementMember
2013-01-01
2013-01-31
0000850261
2012-06-30
0000850261
2013-03-22
0000850261
2012-01-01
2012-12-31
0000850261
srne:TwoThousandNineNonEmployeeDirectorGrantsMember
2012-01-01
2012-12-31
0000850261
srne:TwoThousandNineStockIncentivePlanMember
2012-01-01
2012-12-31
srne:Number_of_Grants
iso4217:USD
xbrli:shares
srne:Installment
xbrli:pure
xbrli:shares
iso4217:USD
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 1 - us-gaap:BusinessCombinationDisclosureTextBlock-->
<!-- xbrl,ns -->
<!-- xbrl,nx -->
<font style="font-family:times new roman" size="2"><b></b></font>
<font style="font-family:times new roman" size="2"><b></b></font>
<font style="font-family:times new roman" size="2">
<b></b></font>
<p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>1. Reverse Merger Transaction and Accounting </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Reverse Merger Transaction </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
On September 21, 2009, QuikByte Software, Inc., a Colorado corporation and shell company, or QuikByte, acquired Sorrento Therapeutics, Inc., a privately held Delaware corporation, or STI, in a
reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of STI common stock were converted, at an exchange ratio of 25.48433-for-1, into an aggregate of 169,375,807 shares of QuikByte common stock and STI
became a wholly owned subsidiary of QuikByte. The holders of QuikByte’s common stock as of immediately prior to the Merger held an aggregate of 55,708,320 shares of QuikByte’s common stock, which consisted of: (i) 11,073,946 shares of
common stock outstanding as of September 17, 2009, and (ii) 44,634,374 shares of common stock issued on September 18, 2009 in connection with a $2.0 million private placement. The accompanying financial statements share and per share
information has been retroactively adjusted to reflect the exchange ratio in the Merger. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">STI was originally incorporated as
San Diego Antibody Company in California in 2006 and was renamed Sorrento Therapeutics, Inc. and reincorporated in Delaware in 2009, prior to the Merger. QuikByte was originally incorporated in Colorado in 1989. Following the Merger, on
December 4, 2009, QuikByte reincorporated under the laws of the State of Delaware, or the Reincorporation. Immediately following the Reincorporation, on December 4, 2009, STI merged with and into QuikByte, the separate corporate existence
of STI ceased and QuikByte continued as the surviving corporation, or the Roll-Up Merger. Pursuant to the certificate of merger filed in connection with the Roll-Up Merger, QuikByte’s name was changed from “QuikByte Software, Inc.” to
“Sorrento Therapeutics, Inc.”, or the Company. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Reverse Merger Accounting </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Immediately following the consummation of the Merger, the: (i) former security holders of STI common stock had an approximate 75%
voting interest in QuikByte and the QuikByte stockholders retained an approximate 25% voting interest, (ii) former executive management team of STI remained as the only continuing executive management team for the Company, and
(iii) Company’s ongoing operations consist solely of the ongoing operations of STI. Based primarily on these factors, the Merger was accounted for as a reverse merger and a recapitalization in accordance with generally accepted accounting
principles in the U.S., or GAAP. As a result, these financial statements reflect the: (i) historical results of STI prior to the Merger, (ii) combined results of the Company following the Merger, and (iii) acquired assets and
liabilities at their historical cost, which approximates their fair value at the Merger date. In connection with the Merger, the Company received cash of $104,860, other current assets of $20,150 and assumed accounts payable of $24,624. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 2 - us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>2. Nature of Operations and Summary of Significant Accounting Policies </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Nature of Operations and Basis of Presentation </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is a biopharmaceutical company focused on the discovery, development and commercialization of novel and proprietary
biotherapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. The Company’s objective is to either independently or through one or more partnerships with pharmaceutical
or biopharmaceutical organizations identify drug development candidates derived from the libraries. See Note 10. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of
December 31, 2012, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is
considered to be in the development stage. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying
consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary, Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sorento Hong Kong had
no operations in 2012. All inter-company balances and transactions have been eliminated in consolidation. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Liquidity and Going Concern </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the
realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has a net loss of $4,845,308, net cash used for operations of
$3,797,476 and net cash used for investing activities of $547,884, for the year ended December 31, 2012. As of December 31, 2012, the Company also has an accumulated deficit of $10,950,299 and working capital of $4,667,817. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In February 2013, the Company entered into a loan and security agreement with a bank which provided the Company with an equipment loan
for up to $1,000,000. In March 2013, the Company entered into: (i) a stock purchase agreement and issued 33,658,305 shares of common stock for aggregate gross proceeds of $6,418,495 and (ii) the transactions with IgDraSol, Inc.
(IgDraSol). The Company intends to acquire IgDraSol in 2013. See Note 10. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company anticipates that it will continue to
incur net losses into the foreseeable future as it: (i) continues to identify and advance a number of potential drug candidates into preclinical development activities, (ii) acquires IgDraSol and continues to fund its operations, and (iii) expands
its corporate infrastructure, including the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations beyond October 2013. These conditions
give rise to substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt
financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is
unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company
does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction
to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If the Company
raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment
obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Use of Estimates </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these
estimates. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Cash and Cash Equivalents </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The
Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced
any losses on such accounts. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Fair Value of Financial Instruments </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company’s financial instruments consist of cash and cash equivalents, grants receivable, prepaid expenses and other assets,
accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of
significant judgment and therefore cannot be determined with precision. As of December 31, 2012 and 2011, the carrying amount of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable, accrued
liabilities and deferred revenue are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Grants Receivable </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
Grants receivable at December 31, 2012 and 2011 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the
National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are
charged to operations. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Property and Equipment </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the
straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Impairment of Long-Lived Assets </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company evaluates its long-lived assets with definite lives, such as property and equipment, for impairment. The Company records
impairment losses on long-lived assets used for operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the carrying value of the assets. There have not been any
impairment losses of long-lived assets through December 31, 2012. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Research and Development Costs </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services,
stock-based compensation expense, salaries and related benefits. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Income Taxes </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax
position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and
liabilities and the related financial amounts, using currently enacted tax rates. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has deferred tax assets, which
are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the
deferred tax assets annually. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Revenue Recognition </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The Company’s inception to date revenues are generated from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration
Agreement, that the Company entered into with a third party in July 2010. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where
applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the
grant. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The revenue from the Collaboration Agreement is derived from the completion of certain development services and the
reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive
evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to
satisfying the Company’s revenue recognition criteria are recorded as deferred revenue. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Stock-Based Compensation </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity
instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over
the employee’s requisite service period (generally the vesting period of the equity grant). </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for
equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated
fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related
services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Comprehensive Income (Loss) </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from
non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss),
including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2012 and 2011, the
comprehensive loss was equal to the net loss. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Net Loss Per Share </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss
per share includes the impact of potentially dilutive securities. During 2012 and 2011, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted
net loss per share, as their effect would have been anti-dilutive. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">These outstanding securities
consist of the following: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="68%"> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Years Ended December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unvested Restricted Common stock subject to repurchase</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">336,454</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,677,430</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,490,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,947,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding warrants</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average exercise price of options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.14</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.12</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<!-- End Table Body -->
</table>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 3 - us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock-->
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>3. Property and Equipment </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Property and equipment consisted of the following as of December 31, 2012 and 2011:
</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="67%"> </td>
<td valign="bottom" width="8%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Furniture and fixtures</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,739</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,739</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Office equipment</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">23,039</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,691</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Lab equipment</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,855,220</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,136,778</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Leasehold improvements</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">65,679</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,623</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,959,677</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,173,831</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less accumulated depreciation and amortization</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(478,688</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(185,386</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,480,989</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">988,445</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Depreciation expense for the years ended December 31, 2012 and 2011 and for the period from inception (January 25,
2006) (“Inception”) through December 31, 2012 was $293,302, $159,219 and $478,689, respectively. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 4 - srne:SignificantAgreementsAndContractsTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>4. Significant Agreements and Contracts </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>License Agreement with OPKO Health, Inc. </i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In June 2009, the Company entered into a limited license agreement, or the OPKO License, with OPKO Health, Inc., or OPKO, pursuant to which the Company granted OPKO an exclusive, royalty-free, worldwide
license under all U.S. and foreign patents and patent applications owned or controlled by the Company or any of its affiliates, or the STI Patents, to: (i) develop, manufacture, use, market, sell, offer to sell, import and export certain
products related to the development, manufacture, marketing and sale of drugs for ophthalmological indications, or the OPKO Field, and (ii) use and screen any population of distinct molecules covered by any claim of the STI Patents or which is
derived by use of any process or method covered by any claim of the STI Patents to identify, select and commercialize certain products within the OPKO Field. Subject to certain limitations, OPKO will have the right to sublicense the foregoing rights
granted under the OPKO License. Additionally, pursuant to the OPKO License, OPKO has granted the Company an exclusive, royalty-free, worldwide license to any patent or patent application owned or controlled by OPKO or any of its affiliates to
develop, use, make, market, sell and distribute certain products in any field of use, other than the OPKO Field, or the OPKO Patents. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The Company has retained all rights to the STI Patents outside of the OPKO Field and has agreed not to practice the OPKO Patents or the STI Patents outside the STI current field of use. Unless otherwise
terminated in accordance with its terms, the License Agreement will expire upon the expiration of the last to expire patent within the STI Patents and OPKO Patents on a country-by-country basis. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>License Agreement with The Scripps Research Institute </i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In January 2010, the Company entered into a license agreement, or the TSRI License, with The Scripps Research Institute, or TSRI. Under the TSRI License, TSRI granted the Company an exclusive, worldwide
license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus (“Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the
Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved, (iii) agreed to pay a royalty on any sales of licensed products by the Company or its
affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the
agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days notice to TSRI and TSRI may terminate
the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or
both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For the years ended December 31, 2012 and 2011 and for the period from Inception
through December 31, 2012, the Company recorded $41,835, $4,991 and $127,345 in patent prosecution and maintenance costs associated with the TSRI License, respectively, which has been included in general and administrative expenses. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The fair value of the warrants to purchase Company common stock, issued in connection with the TSRI License in 2010, of $17,989 was
determined using the Black-Scholes valuation model with the following weighted-average assumptions: risk-free interest rate of 2.48%, no dividend yield, expected term of 10 years, and volatility of 102%. Such fair value has been included in general
and administrative expenses for the period from Inception through December 31, 2012. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>NIH Grants </i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In May 2010, the NIAID awarded the Company an Advanced Technology Small Business Technology Transfer Research grant to support the
Company’s program to generate and develop novel antibody therapeutics and vaccines to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant award. The project period for Phase 1 of the Staph Grant award covers a
two-year period which commenced in June 2010 and ended in May 2012. The Company records revenue associated with the NIH Grants as the related costs and expenses are incurred. During the years ended December 31, 2012 and 2011 and for the period
from Inception through December 31, 2012, the Company recorded $119,379, $215,986 and $600,000 of revenue associated with the Staph Grant award, respectively. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In July 2011, the NIAID awarded the Company a second Advanced Technology Small Business Technology Transfer Research grant to support the Company’s program to generate and develop antibody
therapeutics and vaccines to combat C. difficile infections, or the C. difficile Grant award. The project period for the C. difficile Grant award covers a two-year period which commenced in June 2011, and as of September 30, 2012, the entire
Phase 1 grant of $600,000 had been awarded. During the years ended December 31, 2012 and 2011 and for the period from Inception through December 31, 2012, the Company recorded $335,579, $113,198 and $448,777 of revenue associated with the
C. difficile Grant award, respectively. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In June 2012, the NIAID awarded the Company a third Advanced Technology Small
Business Technology Transfer Research grant, with an initial award of $300,000, to support the Company’s program to generate and develop novel human antibody therapeutics to combat Staph infections, including Methicillin-resistant Staph, or the
Staph Grant II award. The project period for the phase I grant covers a two-year period which commenced in June 2012, with a potential annual award of $300,000 per year. During the year ended December 31, 2012 and for the period from Inception
through December 31, 2012, the Company recorded $128,816 of revenue associated with the Staph Grant II award. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Collaboration Agreement
</i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In July 2010, the Company entered into the Collaboration Agreement, with a third party. Under the terms of the
Collaboration Agreement, the Company provided certain antibody screening services for an upfront cash fee of $200,000 and was reimbursed for certain costs and expenses associated with providing the services, or the Development Costs. The upfront fee
and reimbursable Development Costs were accounted for as separate units of accounting. The Company recorded the gross amount of the reimbursable Development Costs as revenue and the costs associated with these reimbursements are reflected as a
component of research and development expense. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Any amounts received by the Company pursuant to the Collaboration Agreement
prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue. For the years ended December 31, 2012 and 2011 and for the period from Inception through December 31, 2012, the Company recognized $0,
$200,000 and $223,453, respectively. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Assignment Agreement </i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Subsequent to year end, in January 2013, the Company entered into an Assignment Agreement, or the Assignment Agreement, with Tien-Li Lee,
M.D. and Jane Wu Lee, M.D. as individuals (collectively, the Lees) pursuant to which the Lees agreed to assign to the Company their right, title and interest throughout the world in and to certain inventions and patents that provide for the
production of recombinant intravenous immunoglobulin. As consideration for the assignment by the Lees under the Assignment Agreement, the Company: (i) issued the Lee’s 250,000 shares of the Company’s common stock upon execution of the
Agreement, (ii) agreed to pay the Lees a total of $50,000 in five monthly installments of $10,000 beginning on February 1, 2013, and (iii) agreed to issue the Lees up to 2,000,000 shares of the Company’s common stock based upon
the achievement of certain milestone events described in the Assignment Agreement. Unless otherwise terminated in accordance with its terms, the Assignment Agreement will expire upon the expiration of the last to expire patent within the assigned
patent rights. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>U.S. Treasury Grants </i></b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
During 2010, the U.S. Treasury awarded the Company two one-time grants totaling $394,480 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The
grants cover reimbursement for qualifying expenses incurred by the Company in 2010 and 2009. The proceeds from these grants are classified in “Revenues—Grant” in the Inception through December 31, 2012 consolidated statement of
operations. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 5 - us-gaap:DebtDisclosureTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>5. Loan and Security Agreement </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Subsequent to year end, in February 2013, the Company entered into a loan and security agreement with a bank pursuant
to which the lender provided the Company loans to finance certain equipment, in an aggregate principal amount of up to $1,000,000. Under the loan agreement, the lender funded the initial equipment advance in the principal amount of $875,888 in
February 2013 and agreed to fund, subject to customary conditions, an additional equipment advance in the principal amount of $124,112 on or prior to August 21, 2013. The loans under the loan agreement bear interest at a rate equal to the
three-year U.S. Treasury note yield plus 4.65%, which is fixed on the date of each funding. Interest accrues on the initial outstanding advance at the fixed rate of 5.15%. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The Company is obligated to pay interest-only on any loans funded under the loan agreement prior to April 30, 2013 until May 1, 2013, and thereafter to pay 36 consecutive equal monthly
installments of principal and interest through April 1, 2016. The Company is obligated to pay equal monthly installments of principal and interest through April 1, 2016 on any loans funded under the loan
agreement after April 30, 2013. All loans funded under the loan agreement mature on April 1, 2016. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">At the
Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the
event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay a final fee of $55,000. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company granted the lender a security interest in any equipment that is financed under the loan agreement. The Company is also
subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed
by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified
subordinated debt. In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Future annual principal payments under the loan agreement are as
follows: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2013</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">194,642</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2014</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">291,963</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2015</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">291,963</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2016</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">97,320</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total payments</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">875,888</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 6 - srne:StockholdersEquityDeficitAndRelatedPartyTransactionTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>6. Stockholders’ Equity (Deficit) and Related Party Transaction </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Common Stock </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In February 2006, in conjunction with the founding of the Company, 101,937,315 shares of common stock were issued to founders, at the pre-Merger par value, for total consideration of $400 in cash.
</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In March 2009, the Company issued 7,403,861 shares of restricted common stock to certain consultants, at the pre-Merger par
value, for aggregate gross proceeds of $291. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In March 2009, the Company issued 1,019,374 shares of unrestricted common stock
to certain consultants for aggregate cash gross proceeds of $10 and issued a note receivable for $30. The note was paid in full in 2010. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In June 2009, the Company issued 59,015,257 shares of common stock at $0.039 per share for aggregate gross proceeds of $2.3 million to OPKO in a private placement transaction. Related stock issuance costs
totaled $25,999. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In September 2009, and in connection with the Merger, the Company: (i) issued 44,634,374 shares of
common stock, in a private placement transaction, at $0.0448 per share for aggregate gross proceeds of $1,999,620, and (ii) issued 11,073,946 shares of common stock to the former stockholders of QuikByte in exchange for the net assets of
QuikByte as well as all of their outstanding shares in QuikByte immediately prior to the Merger. Total stock issuance and Merger costs totaled $168,767. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In December 2010,
the Company issued 25,717,143 shares of common stock, in a private placement transaction, at $0.14 per share for aggregate gross proceeds of $3.6 million. Related stock issuance costs were estimated at $159,905. In 2011, the Company reduced its
stock issuance costs accrued in 2010 by $80,039. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In December 2011, the Company entered into a Stock Purchase Agreement and
issued 12,500,000 shares of common stock, in a private placement transaction, at $0.16 per share for aggregate gross proceeds of $2,000,000. In May 2012, pursuant to the Stock Purchase Agreement, as amended and restated, the Company issued
37,500,000 shares of common stock, in a private placement transaction, at $0.16 per share for aggregate gross proceeds of $6,000,000. 6,250,000 of the shares were purchased by an investor, Hongye SD Group, LLC, of which Dr. Henry Ji, the
Company’s Chief Executive Officer and President, is a managing director. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Subsequent to year end, in March 2013, the
Company entered into a Stock Purchase Agreement and issued 33,658,305 shares of common stock, in a private placement transaction, at $0.18 per share for aggregate gross proceeds of $6,418,495. See Note 10. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Stock Incentive Plans </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>2009 Equity
Incentive Plan </i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In February 2009, prior to the Merger, the Company’s Board of Directors approved the 2009 Equity
Incentive Plan, or the EIP, under which 10,000,000 shares of common stock were reserved for issuance to employees, non-employee directors and consultants of the Company. The EIP provided for the grant of incentive stock options, non-incentive stock
options, restricted stock awards and stock bonus awards to eligible recipients. In March 2009, the Company issued 7,403,861 restricted common stock awards to certain consultants for aggregate gross proceeds of $291. The restricted shares vest
monthly over four years and the Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. Any unvested shares immediately vest in the event of a merger, sale, or other
transaction resulting in a change in control of the Company. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">At December 31, 2012, 336,454 shares were unvested and
subject to repurchase by the Company. The Company has the right of first refusal to purchase any proposed disposition of shares issued under the EIP. As a result of the Merger, no further shares are available for grant under the EIP. In January
2011, the Company repurchased 1,104,135 unvested shares of restricted common stock for $43. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>2009 Non-Employee Director Grants
</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved
the reservation and issuance of 200,000 nonstatutory stock options to the Company’s non-employee directors. The outstanding options vested on the one year anniversary of the vesting commencement date in October 2010. Such options are
exercisable for up to 10 years from the grant date. No further shares are available for grant under this plan. The aggregate intrinsic value for such options as of December 31, 2012 was $10,816. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table summarizes stock option activity
as of December 31, 2011 and 2012, and the changes for the years then ended: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="76%"> </td>
<td valign="bottom" width="6%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="6%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options<br />Outstanding</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise Price</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2010</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">120,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2011</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">120,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding, Vested and Exercisable at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><i>2009 Stock Incentive Plan </i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan, or the Stock Plan, which became effective in December 2009 and under which 12,000,000 shares of the Company’s
common stock were initially reserved for issuance to employees, non-employee directors and consultants of the Company. Pursuant to the terms of the Stock Plan, such initial amount will be automatically increased annually on the first day of each
fiscal year, beginning in 2011, by the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 1,200,000 shares, or (iii) an
amount approved by the administrator of the Stock Plan. As of December 31, 2012, 14,400,000 shares of the Company’s common stock were reserved for issuance. The Stock Plan provides for the grant of incentive stock options, non-incentive
stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the
Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants will generally
vest 25% on each anniversary of the original vesting date over four years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not
exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of the Company’s common stock issued in connection with an early exercise however, may be
repurchased by the Company upon termination of the optionee’s service with the Company. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table summarizes stock option activity
as of December 31, 2011 and 2012, and the changes for the years then ended: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="60%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options<br />Outstanding</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise Price</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate Intrinsic<br />Value</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2010</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,960,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.09</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,780,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.14</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(762,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.11</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(150,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.09</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2011</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,827,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.12</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">115,700</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,535,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.16</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(722,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.15</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(230,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.13</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,410,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.15</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Vested and Exercisable at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,320,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.13</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">54,750</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company uses the Black-Scholes valuation model to calculate the fair value of stock options.
The fair value of employee stock options was estimated at the grant date using the following assumptions: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="69%"> </td>
<td valign="bottom" width="14%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="13%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Years Ended December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average grant date fair value</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.29</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.11</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividend yield</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">103</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.88</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.41</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life of options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.5 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.7 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable
future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was
based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the
contractual term and the weighted average vesting term of the options. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The total employee stock-based compensation recorded
as operating expenses was $324,958, $42,293, and $418,816 for the years ended December 31, 2012 and 2011 and for the period from Inception through December 31, 2012, respectively. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The total unrecognized compensation cost related to unvested stock option grants as of December 31, 2012 was $1,782,054 and the
weighted average period over which these grants are expected to vest is 3.4 years. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company records equity instruments
issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense
related to non-employee consultants recorded as operating expenses was $538,169, $255,741, and $1,047,823 for the years ended December 31, 2012 and 2011 and for the period from Inception through December 31, 2012, respectively. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Common Stock Reserved for
Future Issuance </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Common stock reserved for future issuance consists of the following at
December 31, 2012: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common stock warrants outstanding under the TSRI License</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common stock options outstanding under the EIP</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Authorized for future grant or issuance under the Stock Plan</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,020,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,300,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 7 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>7. Commitments and Contingencies </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Litigation </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Management is currently not aware of any pending lawsuits. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Operating Lease </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The
Company leases its corporate office and laboratory space under a non-cancelable operating lease that, as amended, expires on September 30, 2014. The lease contains an option to extend the term by four years at the then prevailing rate.
Effective April 1 2012, the Company entered into a supplemental amendment to add additional rental space, which expires in April 2017. This supplemental amendment contains an option to extend the term for the additional rental space by five
years at the then prevailing rate. Through the end of the initial lease term, the lease provides for an average monthly base rent of $11,792 with scheduled annual base rent increases of 2.75%-3.00% over the initial lease term. For the additional
rental space, the average monthly base rent beyond the initial term of the lease is $2,332. The Company has provided a security deposit of $22,757 to secure its obligations under the lease, which has been included in other assets in the accompanying
financial statements. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Minimum future non-cancelable annual operating
lease obligations are as follows for the years ending December 31: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2013</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">144,864</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2014</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">117,101</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2015</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">26,532</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2016</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">28,944</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2017</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,648</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">327,089</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Rental expense paid for the years ended December 31, 2012 and 2011 and for the period from Inception through
December 31, 2012 under the above lease totaled $128,300, $102,037 and $335,184, respectively. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 8 - us-gaap:IncomeTaxDisclosureTextBlock-->
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>8. Income Taxes </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company’s net deferred tax assets are as follows as of December 31, 2012 and 2011: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="76%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred tax assets:</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net operating loss carryforwards and credits</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,047,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,404,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock based compensation</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">97,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">46,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued expenses and other</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(99,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(19,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total deferred tax assets</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,045,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,431,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less valuation allowance</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,045,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,431,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net deferred tax assets</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2"> —</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2"> —</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including
the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the
Company maintains a valuation allowance of $5,045,000 against its deferred tax assets as of December 31, 2012. Realization of the deferred tax assets will be primarily dependent upon the Company’s ability to generate sufficient taxable income
prior to the expiration of its net operating losses. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of December 31 2012, the Company had net operating loss
carryforwards of approximately $10,500,000 and $9,209,000 for federal and state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in varying amounts in 2027 to 2032. The Company also has
research and development credits of approximately $307,000 and $355,000 for federal and state income tax purposes, respectively. The federal credits may be used to offset future taxable income and will begin to expire in varying amounts in 2029 to
2032. The state credits may be used to offset future taxable income, such credits carryforward indefinitely. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is
subject to taxation in the U.S. and California jurisdictions. Currently, no historical years are under examination. The Company’s tax years ending December 31, 2012 and 2011 are subject to examination by the U.S. and state taxing
authorities due to the carryforward of unutilized net operating losses and research and development credits. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Utilization of
the Company’s net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to an “ownership change” that may have occurred, or that could occur in the future,
as defined and required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research
and development credit carryforwards, and other tax attributes that can be utilized annually to offset future taxable income and tax, respectively. Any limitation may result in the expiration of a portion of the net operating loss carryforwards or
research and development credit carryforwards before utilization. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In general, an “ownership change” results from a
transaction or series of transactions over a three-year period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public groups. The Company intends to complete a study in the future to
assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation, and will complete such study before the use of any of the aforementioned attributes. </font></p>
<p style="font-size:1px;margin-top:18px;margin-bottom:0px"> </p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 9 - us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock-->
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>9. 401(k) Plan </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. Through December 31, 2012, no such
contributions were made. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 10 - us-gaap:SubsequentEventsTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>10. Subsequent Events </b></font></p>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Assignment Agreement </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In January 2013, the Company entered into an Assignment Agreement, or the Assignment Agreement with Tien-Li Lee, M.D. and Jane Wu Lee, M.D. as individuals (collectively, the Lees) pursuant to which the
Lees agreed to assign to the Company their right, title and interest throughout the world in and to certain inventions and patents that provide for the production of recombinant intravenous immunoglobulins. See Note 4. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Loan and Security Agreement </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
In February 2013, the Company entered into a loan and security agreement with a bank which provided the Company with an equipment loan for up to $1,000,000 (see Note 5). </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Stock Purchase Agreement </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In March 2013, the Company entered into a stock purchase agreement and issued 33,658,305 shares of common stock for aggregate gross
proceeds of $6,418,495 million. See Note 6. </font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>IgDraSol Transactions </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
On March 7, 2013, the Company entered into an exclusive option agreement with IgDraSol, a private company focused on the development of oncologic agents for the treatment of metastatic breast cancer,
or MBC, non-small cell lung cancer, or NSCLC, and other cancers. Pursuant to the option agreement, IgDraSol granted the Company an irrevocable option to acquire IgDraSol by means of an agreement and plan of merger. In consideration for entering into
the option agreement, IgDraSol is to receive a non refundable lump sum payment of $200,000. The close of the transaction and the lump sum payment are expected to occur within 51 days of the signing of the option agreement. If the Company exercises
its option to acquire IgDraSol, the Company will, pursuant to the merger agreement, issue 76,199,198 shares of common stock to IgDraSol stockholders and, upon the later achievement of a specified regulatory milestone, the Company will issue an
additional 32,656,799 shares of common stock to former IgDraSol stockholders. If the Company does not exercise its option to acquire IgDraSol, the Company will be required to invest $500,000 in IgDraSol pari passu with other new investors of
IgDraSol. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><font style="font-family:times new roman" size="2">IgDraSol’s lead compound, Cynviloq™, is a micellar diblock copolymeric paclitaxel formulation drug product.
Cynviloq™ is currently approved and marketed in several countries, including South Korea for MBC and NSCLC under the trade name Genexol-PM<font style="font-family:times new roman" size="1"><sup>
®</sup></font>, and has completed Phase 2 testing for potential advancement into registration trials in the U.S. IgDraSol has the exclusive U.S. distribution rights to
Cynviloq™ from Samyang Biopharmaceuticals Corporation, a South Korean corporation. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><font style="font-family:times new roman" size="2">Contemporaneously with the execution of the option agreement, on March 7, 2013, the Company and IgDraSol
entered into an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol<font style="font-family:times new roman" size="1">
<sup>®</sup></font> and related technologies for a purchase price of $1,210,000. The transaction is expected to close within 45 days of
the signing of the asset purchase agreement. Upon payment of such purchase price, IgDraSol and the Company intend to enter into a development services agreement pursuant to which approximately $3,000,000 in development services may be provided by
IgDraSol for the development of Tocosol<font style="font-family:times new roman" size="1"><sup>®</sup></font> and related technologies. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">IgDraSol and the Company also entered into an initial services agreement dated March 7, 2013, or the initial services agreement,
pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform in exchange for a payment of $1,000,000, which was paid to IgDraSol upon signing. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table1 - srne:NatureOfOperationsAndBasisOfPresentationPolicyTextBlock-->
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Nature of Operations and Basis of Presentation </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company is a biopharmaceutical company focused on the discovery, development and commercialization of novel and proprietary
biotherapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. The Company’s objective is to either independently or through one or more partnerships with pharmaceutical
or biopharmaceutical organizations identify drug development candidates derived from the libraries. See Note 10. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">As of
December 31, 2012, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure, and has not realized revenues from its planned principal operations. Accordingly, the Company is
considered to be in the development stage. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The accompanying
consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary, Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sorento Hong Kong had
no operations in 2012. All inter-company balances and transactions have been eliminated in consolidation. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table2 - us-gaap:LiquidityDisclosureTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Liquidity and Going Concern </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue to operate as a going concern and which contemplates the
realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has a net loss of $4,845,308, net cash used for operations of
$3,797,476 and net cash used for investing activities of $547,884, for the year ended December 31, 2012. As of December 31, 2012, the Company also has an accumulated deficit of $10,950,299 and working capital of $4,667,817. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">In February 2013, the Company entered into a loan and security agreement with a bank which provided the Company with an equipment loan
for up to $1,000,000. In March 2013, the Company entered into: (i) a stock purchase agreement and issued 33,658,305 shares of common stock for aggregate gross proceeds of $6,418,495 and (ii) the transactions with IgDraSol, Inc.
(IgDraSol). The Company intends to acquire IgDraSol in 2013. See Note 10. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company anticipates that it will continue to
incur net losses into the foreseeable future as it: (i) continues to identify and advance a number of potential drug candidates into preclinical development activities, (ii) acquires IgDraSol and continues to fund its operations, and (iii) expands
its corporate infrastructure, including the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations beyond October 2013. These conditions
give rise to substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt
financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is
unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company
does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction
to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">If the Company
raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment
obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table3 - us-gaap:UseOfEstimates-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Use of Estimates </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these
estimates. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table4 - us-gaap:CashAndCashEquivalentsPolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Cash and Cash Equivalents </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The
Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced
any losses on such accounts. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table5 - us-gaap:FairValueOfFinancialInstrumentsPolicy-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Fair Value of Financial Instruments </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company’s financial instruments consist of cash and cash equivalents, grants receivable, prepaid expenses and other assets,
accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of
significant judgment and therefore cannot be determined with precision. As of December 31, 2012 and 2011, the carrying amount of cash and cash equivalents, grants receivable, prepaid expenses and other assets, accounts payable, accrued
liabilities and deferred revenue are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table6 - srne:GrantsReceivablePolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Grants Receivable </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
Grants receivable at December 31, 2012 and 2011 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the
National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are
charged to operations. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table7 - us-gaap:PropertyPlantAndEquipmentPolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Property and Equipment </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the
straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table8 - us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-->
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Impairment of Long-Lived Assets </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company evaluates its long-lived assets with definite lives, such as property and equipment, for impairment. The Company records
impairment losses on long-lived assets used for operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the carrying value of the assets. There have not been any
impairment losses of long-lived assets through December 31, 2012. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table9 - us-gaap:ResearchAndDevelopmentExpensePolicy-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Research and Development Costs </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services,
stock-based compensation expense, salaries and related benefits. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table10 - us-gaap:IncomeTaxPolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Income Taxes </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether
tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax
position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and
liabilities and the related financial amounts, using currently enacted tax rates. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company has deferred tax assets, which
are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the
deferred tax assets annually. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table11 - us-gaap:RevenueRecognitionPolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Revenue Recognition </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
The Company’s inception to date revenues are generated from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration
Agreement, that the Company entered into with a third party in July 2010. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where
applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the
grant. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The revenue from the Collaboration Agreement is derived from the completion of certain development services and the
reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive
evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to
satisfying the Company’s revenue recognition criteria are recorded as deferred revenue. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table12 - us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy-->
<p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Stock-Based Compensation </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity
instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over
the employee’s requisite service period (generally the vesting period of the equity grant). </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The Company accounts for
equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated
fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related
services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table13 - us-gaap:ComprehensiveIncomePolicyPolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Comprehensive Income (Loss) </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from
non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss),
including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2012 and 2011, the
comprehensive loss was equal to the net loss. </font></p>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Accounting Policy: note2_accounting_policy_table14 - us-gaap:EarningsPerSharePolicyTextBlock-->
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>Net Loss Per Share </b></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">
Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss
per share includes the impact of potentially dilutive securities. During 2012 and 2011, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted
net loss per share, as their effect would have been anti-dilutive. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">These outstanding securities
consist of the following: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="68%"> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Years Ended December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unvested Restricted Common stock subject to repurchase</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">336,454</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,677,430</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,490,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,947,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding warrants</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average exercise price of options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.14</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.12</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note2_table1 - us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-->
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">These outstanding securities
consist of the following: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="68%"> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="12%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Years Ended December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unvested Restricted Common stock subject to repurchase</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">336,454</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,677,430</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,490,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,947,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding warrants</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted average exercise price of options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.14</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.12</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note3_table1 - us-gaap:PropertyPlantAndEquipmentTextBlock-->
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Property and equipment consisted of the following as of December 31, 2012 and 2011:
</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="67%"> </td>
<td valign="bottom" width="8%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Furniture and fixtures</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,739</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,739</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Office equipment</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">23,039</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,691</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Lab equipment</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,855,220</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,136,778</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Leasehold improvements</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">65,679</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,623</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,959,677</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,173,831</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less accumulated depreciation and amortization</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(478,688</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(185,386</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,480,989</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">988,445</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note5_table1 - us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-->
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Future annual principal payments under the loan agreement are as
follows: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2013</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">194,642</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2014</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">291,963</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2015</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">291,963</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2016</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">97,320</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total payments</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">875,888</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note6_table1 - us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-->
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table summarizes stock option activity
as of December 31, 2011 and 2012, and the changes for the years then ended: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="76%"> </td>
<td valign="bottom" width="6%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="6%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options<br />Outstanding</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise Price</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2010</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">120,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2011</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">120,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">40,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding, Vested and Exercisable at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.0448</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note6_table2 - us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-->
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">The following table summarizes stock option activity
as of December 31, 2011 and 2012, and the changes for the years then ended: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="60%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Options<br />Outstanding</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Weighted-<br />Average<br />Exercise Price</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Aggregate Intrinsic<br />Value</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2010</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,960,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.09</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,780,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.14</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(762,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.11</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(150,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.09</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2011</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,827,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.12</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">115,700</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Granted</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,535,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.16</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Canceled</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(722,500</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.15</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options Exercised</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(230,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.13</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Outstanding at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">10,410,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.15</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Vested and Exercisable at December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,320,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.13</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">54,750</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note6_table3 - us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-->
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:times new roman" size="2">
The fair value of employee stock options was estimated at the grant date using the following assumptions: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="69%"> </td>
<td valign="bottom" width="14%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="13%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Years Ended December 31,</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Weighted-average grant date fair value</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.29</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.11</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Dividend yield</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">—</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Volatility</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">103</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">102</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Risk-free interest rate</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">0.88</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2.41</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">% </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Expected life of options</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.5 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5.7 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note6_table4 - srne:CommonStockReservedForFutureIssuanceTableTextBlock-->
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Common stock reserved for future issuance consists of the following at
December 31, 2012: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common stock warrants outstanding under the TSRI License</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">200,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Common stock options outstanding under the EIP</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">80,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Authorized for future grant or issuance under the Stock Plan</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,020,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">14,300,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note7_table1 - us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-->
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Minimum future non-cancelable annual operating
lease obligations are as follows for the years ending December 31: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="68%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="83%"> </td>
<td valign="bottom" width="7%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2013</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">144,864</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2014</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">117,101</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2015</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">26,532</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2016</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">28,944</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">2017</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,648</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">327,089</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note Table: note8_table1 - us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-->
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%">
<font style="font-family:times new roman" size="2">
Significant components of the Company’s net deferred tax assets are as follows as of December 31, 2012 and 2011: </font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px"> </p>
<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">
<!-- Begin Table Head -->
<tr>
<td width="76%"> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
<td valign="bottom" width="4%"> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<!-- End Table Head -->
<!-- Begin Table Body -->
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Deferred tax assets:</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom"> </td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net operating loss carryforwards and credits</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,047,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,404,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Stock based compensation</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">97,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">46,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Accrued expenses and other</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(99,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(19,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total deferred tax assets</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,045,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,431,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Less valuation allowance</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(5,045,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,431,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">) </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#cceeff">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net deferred tax assets</font></p>
</td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2"> —</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:times new roman" size="2"> —</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2"> </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
<!-- End Table Body -->
</table>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">This Amendment No. 1 (this “Amendment”) to the Annual Report on Form 10-K for the period ended December 31, 2012 (the “Form 10-K”) of Sorrento Therapeutics, Inc. is being filed for the purpose of furnishing Exhibit 101 to the Form 10-K in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-K formatted in eXtensible Business Reporting Language (“XBRL”). The Interactive Data File Exhibits were incomplete in the earlier filing. </font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections. </font></p>
<p style="font-size:1px;margin-top:12px;margin-bottom:0px"> </p>
<p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font style="font-family:times new roman" size="2">No attempt has been made in this Amendment to modify or update the other disclosures presented in the Form 10-K. This Amendment does not reflect events occurring after the filing of the Form 10-K (i.e., occurring after March 25, 2013) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed by the registrant with the SEC. Accordingly, this Amendment should be read in conjunction with the Form 10-K and the registrant's other filings with the SEC. </font></p>
true
--12-31
FY
2012
2012-12-31
10-K/A
0000850261
336075440
Yes
Smaller Reporting Company
33667189
Sorrento Therapeutics, Inc.
No
No
2000000
80039
80039
50000
11792
2332
32656799
500000
20150
0.50
30
30
Pursuant to the terms of the Stock Plan, such initial amount will be automatically increased annually on the first day of each fiscal year, beginning in 2011, by the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 1,200,000 shares, or (iii) an amount approved by the administrator of the Stock Plan.
36
80039
2404000
5047000
2012-12-04
1000000
300000
0.039
0.0448
0.14
0.16
0.16
1019374
10
-30
-62
102
11073946
100386
99279
1107
101937315
400
-9794
10194
2017-04
55000
P10Y
0.01
P2Y
0.03
10000
5
1200000
P5Y
P4Y
200000
127345
4991
41835
0.01
P3Y
P2Y
P2Y
P2Y
300000
10
30
291
1210000
3000000
1000000
80039
2
3
25.48433
2000000
0.75
0.25
14400000
P10Y
P1Y
0.25
1047823
255741
538169
25999
168767
159905
43
P60D
200000
248048271
285126056
4667817
224742
439533
88510
77744
46087
66896
185386
478688
10288245
17117718
168767
168767
418816
42293
324958
0
1677430
2947500
200000
336454
10490000
200000
4568828
6781604
3557656
5251990
2009-09-21
169375807
76199198
104860
24624
104860
5277578
3466549
5091312
5091312
-1811029
1624763
14300000
80000
14020000
200000
0.0001
0.0001
500000000
500000000
44634374
262347135
300117135
11073946
55708320
262347135
300117135
26235
30012
0.0465
875888
0.0515
2016-04-01
124112
2431000
5045000
46000
97000
2431000
5045000
19000
99000
0
478689
159219
293302
478689
159219
293302
6104991
10950299
-0.01
-0.02
P3Y4M24D
1782054
0
P10Y
1.02
0.0248
237960
4571393
1201220
1605978
600000
61238
79760
0
4800
800
800
176946
42943
-23171
224679
-7522
10043
-200000
79760
-184807
18522
109393
-15635
76947
28894
5951
7300
335184
102037
128300
2014-09-30
4568828
6781604
359339
584173
0
875888
194642
97320
291963
291963
15500668
1984083
5970123
-1616857
-1051737
-547884
-8792499
-2743375
-3797476
-75801
-75801
-10950299
-16302
-16302
-25745
-25745
-942266
-942266
-1808386
-1808386
-3236491
-3236491
-4845308
-4845308
30
12774719
3771626
5436382
-10979193
-3242442
-4852608
327089
144864
9648
28944
26532
117101
0.0300
0.0275
10500000
9209000
22727
48625
25999
159905
28999
65969
1721717
1051737
547884
0.0001
0.0001
100000000
100000000
29869
80918
15451451
400
291
10
1970958
5934031
291
1999620
3600000
2000000
6000000
6418495
49217
13125
36092
1173831
1136778
15739
10623
10691
1959677
1855220
15739
65679
23039
988445
1480989
P5Y
P3Y
223453
200000
8203326
2570406
3830404
1572073
448777
223453
128816
394480
600000
329184
113198
200000
215986
583774
335579
0
128816
119379
1795526
529184
583774
22757
1466639
298034
863127
P4Y
P4Y
Employee option grants will generally vest 25% on each anniversary of the original vesting date over four years
7403861
7403861
1019374
336454
P5Y8M12D
P5Y6M
1.02
1.03
0.0241
0.0088
10000000
200000
12000000
0
762500
722500
1780000
8535000
0.11
0.29
115700
10816
120000
1960000
120000
2827500
10410000
0.0448
0.09
0.0448
0.12
0.15
54750
80000
2320000
0.0448
0.13
0.12
0.09
0.14
0.0448
0.13
0.11
0.15
0.14
0.16
0.039
0.0448
0.14
0.16
0.16
0.18
0
101937315
101937315
101937315
225084127
250801270
262347135
300117135
54524
54524
250954
250954
298034
298034
863127
863127
0
0
0
0
0
-75401
-75801
-9794
10194
-91703
-92103
-9794
10194
-117448
-117848
-9794
10194
3200731
-30
-1060114
4238367
22508
5083824
-2868500
7927244
25080
4209489
-6104991
10288245
26235
6197431
-10950299
17117718
30012
59015257
101937315
44634374
59015257
11073946
44634374
25717143
25717143
12500000
12500000
37500000
6250000
37500000
250000
33658305
33658305
7403861
150000
150000
40000
230000
270000
2300000
2274001
2000000
2268099
5902
1995537
4463
3440495
3437923
2572
1971001
1969751
1250
5934031
5930281
3750
6418495
291
-449
740
13125
13110
15
36092
36065
27
1104135
1104135
43
-67
110
307000
355000
17989